Mitochondrial fusion exerts KRAS-dependent therapeutic synergy with gemcitabine/nab-paclitaxel in preclinical models of pancreatic cancer

被引：0
|
作者：
Nguyen, Nicholas D. [1 ]
Yu, Meifang [1 ]
Fujimoto, Tara N. [1 ]
Delahoussaye, Abagail [1 ]
Huang, Yanqing [1 ]
Estrada, Manuel A. [1 ]
Taniguchi, Cullen M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
555
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Targeting Mitochondrial Function and Biogenesis in KRAS-Dependent Pancreatic Cancer
    Badejo, Adeleke Modupe
    McCreary, Jordan
    Szlavich, Ellyssa
    True, Heather
    Serrato, Ana
    Love, Quintin
    Malhotra, Ashim
    FASEB JOURNAL, 2017, 31
  • [22] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
  • [23] Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga
    Torregroza-Sanchez, Maria Patricia
    Bedoya-Apraez, Ivan Dario
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (02) : E16 - E18
  • [24] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Tsujimoto, Akiko
    Sudo, Kentaro
    Nakamura, Kazuyoshi
    Kita, Emiri
    Hara, Ryusuke
    Takayama, Wataru
    Ishii, Hiroshi
    Yamaguchi, Taketo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] Pomalidomide Enhanced Antitumor Effect of Gemcitabine and Nab-Paclitaxel for Pancreatic Cancer Cells
    Saito, Nobuhiro
    Shirai, Yoshihiro
    Sugano, Hiroshi
    Horiuchi, Takashi
    Iwase, Ryota
    Haruki, Koichiro
    Shiba, Hiroaki
    Uwagawa, Tadashi
    Ohashi, Toya
    Yanaga, Katsuhiko
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 223 (04) : E142 - E142
  • [26] Efficacy and safety of the TH-302, gemcitabine, and nab-paclitaxel combination in xenograft models of pancreatic cancer
    Sun, Jessica D.
    Liu, Qian
    Ahluwalia, Dharmendra
    Li, Wenwu
    Wang, Yan
    Ruprell, Ayesha S.
    Hart, Charles P.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [27] Gemcitabine and Nab-paclitaxel Induced Complete Response of Advanced Pancreatic Tail Cancer
    Hirakawa, N.
    Itoi, T.
    Sofuni, A.
    Tsuchiya, T.
    Ishii, K.
    Tanaka, R.
    Tonozuka, R.
    Mukai, S.
    Yamamoto, K.
    Asai, Y.
    Matsunami, Y.
    Homma, T.
    Nakatsubo, R.
    PANCREAS, 2021, 50 (07) : 1065 - 1065
  • [28] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H. Ko
    Thach-Giao Truong
    Emily Kantoff
    Kimberly A. Jones
    Elizabeth Dito
    Anna Ong
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 875 - 881
  • [29] The Prognostic Marker of Unresectable Pancreatic Cancer Undergoing Gemcitabine/nab-Paclitaxel Chemotherapy
    Ohno, A.
    Fujimori, N.
    Suehiro, Y.
    Murakami, M.
    Matsumoto, K.
    Teramatsu, K.
    Kojima, F.
    Takamaysu, Y.
    Takaoka, T.
    Oono, M.
    Ogawa, Y.
    PANCREAS, 2019, 48 (10) : 1500 - 1500
  • [30] Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
    Muranaka, Tetsuhito
    Kuwatani, Masaki
    Komatsu, Yoshito
    Sawada, Kentaro
    Nakatsumi, Hiroshi
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Kubota, Yoshimasa
    Kubo, Kimitoshi
    Kawahata, Shuhei
    Kawakubo, Kazumichi
    Kawakami, Hiroshi
    Sakamoto, Naoya
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (03) : 566 - 571
12345